Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Neurology

Volumn 13, Issue 10, 2014, Pages 977-986

  Miller, Aaron E ^a   Wolinsky, Jerry S ^b   Kappos, Ludwig ^c   Comi, Giancarlo ^d   Freedman, Mark S ^e   Olsson, Tomas P ^f   Bauer, Deborah ^g   Benamor, Myriam ^g   Truffinet, Philippe ^g   O'Connor, Paul W ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f KAROLINSKA INSTITUTE   (Sweden)

^g SANOFI   (France)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; TERIFLUNOMIDE; ASPARTATE AMINOTRANSFERASE; CROTONIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; TOLUIDINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAIR DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK REDUCTION; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; BIOASSAY; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CROTONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODELS; TOLUIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907963174     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70191-7     Document Type: Article

References (25)

1. Miller DH, Chard DT, Ciccarelli O Clinically isolated syndromes. Lancet Neurol 2012, 11:157-169.
2. Bates D Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011, 76(1 suppl):S14-S25.
3. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
4. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
5. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:1489-1496.
6. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
7. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012, 10:33-41.
8. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511.
9. Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 2014, 13:25-67.
10. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006, 66:678-684.
11. Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012, 69:183-190.
12. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
13. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009, 8:987-997.
14. Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013, 19:1074-1083.
15. Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014, 74:659-674.
16. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011, 365:1293-1303.
17. Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014, 13:247-256.
18. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler J 2013, 19:1310-1319.
19. ICH harmonised tripartite guideline-guideline for good clinical practice E6(R1) International Conference on Harmonisation Expert Working Group, (accessed March 11, 2014). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
20. Declaration of Helsinki. Ethical principles for medical research involving human subjects World Medical Association, (accessed March 11, 2014). http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
21. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol 2011, 69:292-302.
22. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
23. Common Terminology Criteria for Adverse Events v 3.0 Cancer Therapy Evaluation Program, (accessed March 11, 2014). http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
24. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012, 18:1278-1289.
25. Vermersch P, Czlonkowska A, Grimaldi LME, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2013, 20:705-716.